MICHELLE BURK: Open Payments
NPI 1174607618 · CHESTERFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$240 in 13 payments from 7 companies in 2025. Trend: 2023 $877 · 2024 $490 · 2025 $240
Food & beverage: $240
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 3 | $74 |
| ABBVIE INC. | 3 | $52 |
| Evofem Biosciences, Inc. | 2 | $38 |
| Exeltis, USA Inc. | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Merck Sharp & Dohme LLC | 1 | $15 |
| Organon LLC | 1 | $14 |
Products named: Veozah, Phexxi, LILETTA, SLYND, VRAYLAR, MYFEMBREE, GARDASIL 9, NEXPLANON.
Industry payments across MO — which companies pay providers there.
